Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study

Abstract

We conclude that tigecycline may be an alternative in the salvage treatment of nosocomial multidrug-resistant Acinetobacter spp. meningitis. Acinetobacter spp. Meningitis.

Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis

“…The meta-analysis was performed with 11 studies [13,14,[19][20][21][22][23][24][25][26][27], including a total of 1052 patients (496 patients in polymyxins group and 556 patients in control group). The characteristics of the included studies are listed in Table 1.…”

“…The characteristics of the included studies are listed in Table 1. These 11 studies consisted of 8 retrospective studies [13,14,19,22,[24][25][26][27], 2 RCTs [20,21] and 1 prospective study [23]. The research hospitals are in North America and Europe (USA, Greece, Spain, Turkey, and France), Middle East (Iran, and Israel) and Asia (Taiwan, China, and Thailand).…”

“…The research hospitals are in North America and Europe (USA, Greece, Spain, Turkey, and France), Middle East (Iran, and Israel) and Asia (Taiwan, China, and Thailand). Two studies [25,26] assessed patients with intracranial infections (such as meningitis). One study [13] reported on patients with intra-abdominal infection.…”

“…In 7 studies [13, 14, 19-21, 23, 24], the intravenous (IV) route of administration was used in both polymyxins and control groups. But in the other 4 studies [22,[25][26][27], patients in polymyxins group received IV and intrathecal/intracerebral (IT) polymyxins or IV and inhaled (IH) polymyxins, while patients in control group were given IV antibiotics only. One-month mortality was reported in all studies, clinical and microbiological response was reported in 5 studies.…”

“…The risk of bias was rated as moderate for 2 RCTs [20,21] and one [14] retrospective study, serious for the remaining 8 studies. Seven studies [19,[22][23][24][25][26][27] were at serious risk of bias in the domain of "bias due to confounding". The common confounding factors were comorbidities (especially immunodeficiency), mixed infection sites, antibiotic susceptibility, severity of disease, and empirical treatment.…”